Consensus InMode Ltd.

Stocks

INMD

IL0011595993

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 16:00:00 2026-08-19 EDT			5-day change	1st Jan Change
15.04 ^USD	+0.33%		-1.25%	+2.38%

08-05	InMode Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-05	Earnings Flash (INMD) InMode Ltd. Posts Q2 Adjusted EPS $0.35 per Share, vs. FactSet Est of $0.33	MT

Evolution of the Average Target: InMode Ltd.

Evolution of the Target Price: InMode Ltd.

Changes in Analyst Recommendations: InMode Ltd.

9ab0a2114b3a4efb14a68f0b6ce3fa9._g4T7eKuSLPyXvoRbsZAWzzM0seHDO7RXXPWumjrq_8.jVdwuavBOeaYbqleG_YVN1KJnLfKP6K6GF7g6j6-8dLNTEzdqpYF6YImsw~3db1de72bd67a13e99c8bba7a34daf6e

Analysts' recommendations: InMode Ltd.

06-25	Alert tagged to multiple companies from a research report withdrawn	RE
25-07-30	InMode Q2 revenue misses estimates	RE
25-04-29	UBS Adjusts InMode Price Target to $16.25 From $19, Maintains Neutral Rating	MT
25-04-29	BTIG Research Downgrades InMode to Neutral From Buy	MT
25-04-28	Baird Downgrades InMode to Neutral From Outperform, $16 Price Target; Shares Fall	MT
25-04-14	InMode Unlikely to Meet Street Consensus for Q1 Non-GAAP EPS, Needham Says	MT
25-01-09	Barclays Adjusts Price Target on InMode to $26 From $27, Maintains Overweight Rating	MT
24-11-01	UBS Adjusts Price Target on InMode to $19 From $17, Maintains Neutral Rating	MT
24-10-17	BTIG Initiates InMode at Buy With $25 Price Target	MT
24-10-10	UBS Adjusts Price Target on InMode to $17 From $20, Maintains Neutral Rating	MT
24-07-23	Jefferies Downgrades InMode to Hold From Buy, Adjusts Price Target to $19 From $21	MT
24-07-15	Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating	MT
24-07-12	Canaccord Genuity Adjusts InMode's PT to $16 From $21, Keeps Hold Rating	MT
24-05-03	UBS Adjusts Price Target on InMode to $20 From $26, Maintains Neutral Rating	MT
24-04-12	Barclays Adjusts Price Target on InMode to $33 From $34, Maintains Overweight Rating	MT
24-02-15	Barclays Adjusts Price Target on InMode to $34 From $32, Maintains Overweight Rating	MT
24-02-14	UBS Adjusts InMode Price Target to $26 From $24, Maintains Neutral Rating	MT
24-01-18	Barclays Trims Price Target on InMode to $32 From $33, Maintains Overweight Rating	MT
23-11-03	UBS Downgrades InMode to Neutral From Buy, Cuts Price Target to $24 From $52	MT
23-08-01	Barclays Adjusts Price Target on InMode to $54 From $47, Maintains Overweight Rating	MT
23-07-28	UBS Adjusts InMode Price Target to $52 From $48, Maintains Buy Rating	MT
23-07-28	Baird Adjusts Price Target on InMode to $61 From $53, Maintains Outperform Rating	MT
23-05-04	Barclays Adjusts Price Target on InMode to $47 From $45, Maintains Overweight Rating	MT
23-03-29	UBS Initiates Coverage on InMode With Buy Rating, $40 Price Target	MT
23-02-17	Needham Downgrades InMode to Hold From Buy as Q1 Aesthetics Patient Survey Shows Consumers Cutting Spending on Procedures	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Objective/dr gap
INMODE LTD.	-	+7.85%
THERMO FISHER SCIENTIFIC, INC.		+7.2%
DANAHER CORPORATION		+14.22%
INTUITIVE SURGICAL, INC.		+22.2%
BOSTON SCIENTIFIC CORPORATION		+24.21%
EDWARDS LIFESCIENCES CORPORATION		+10.97%
SIEMENS HEALTHINEERS AG		+14.28%
AGILENT TECHNOLOGIES, INC.		+7.86%
WATERS CORPORATION		+8.66%
GE HEALTHCARE TECHNOLOGIES INC.		+13.59%
Average		+13.10%
Weighted average by Cap.		+13.74%